ESI-08

• Description:

  ESI-08 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC50 of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  Ras

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; MAPK/ERK Pathway

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Metabolic Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/esi-08.html

• Purity:

  98.74

• Solubility:

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  N#CC1=C(C2CCCCC2)N=C(SCC3=CC(C)=CC=C3C)NC1=O

• Molecular Formula:

  C20H23N3OS

• Molecular Weight:

  353.48

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Chen H, et al. 5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP. Bioorg Med Chem Lett. 2012 Jun 15;22 (12) :4038-43.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [301177-43-5]